Stem Cell Heart Injections During Laser Revascularization Surgery for Treatment of Chronic Ischemic Heart Disease
Prospective Controlled Trial of Intra-Myocardial Infusion of Bone Marrow Derived Autologous CD133+ Selected Cells During Trans-Myocardial Laser Revascularization (TMR) in Patients With Chronic Ischemic Heart Disease
Doctors at the University of Kentucky seek participants in a clinical trial of stem cell heart injections in patients receiving trans-myocardial laser revascularization (TMR). The stem cells will be derived from the patient’s own bone marrow, and screened for a particular form of stem cells known to grow into myocardial (heart muscle) tissue, then injected to the target heart tissue with a goal of improving heart function.
The investigatory treatment will happen during the TMR laser treatment, with single injections at the site of each laser channel (~10-20 injections). Prior recovery of the bone marrow aspirate and follow up at baseline, 3, 6, and 12 months is also required.
- Be 18 years of age or older
- Meet study criteria regarding the severity of their chronic ischemic heart disease
THE STUDY INVOLVES:
- Prescreening tests to confirm eligibility and safety of the patient to participate.
- Bone marrow recovery surgery to aspirate bone marrow and retrieve stem cells.
- TMR laser treatment, with single injections of the select stem cells at the site of each laser channel (~10-20 injections).
- Follow up at baseline, 3, 6, and 12 months.
LOCATIONS AND CONTACTS:
The study site is at the University of Kentucky Healthcare in Lexington, KY, (Map).
Contact: Connie Dampier, RN, MPA | 859-323-1781 | [email protected]
Contact: Michael Sekela, MD | 859-323-6494 | [email protected]
Or go online: